Randomized controlled study to evaluate the sedative effect of rimazolam in patients with mechanical ventilation for septic shock

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045953

Enrollment

Unknown

Registered

2021-04-30

Start date

2021-09-01

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

septic shock

Interventions

experimental group:Remimazolam tosilate for injection

control group:Dexmedetomidine sedation

Eligibility

Sex/Gender

All

Age

20 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20 to 85 years; 2. Estimated mechanical ventilation > for 24 hours; 3. BMI < 40 kg/m 2; 4. Voluntarily sign the informed consent and participate in the study.

Exclusion criteria

Exclusion criteria: 1. Coma patients with craniocerebral injury; 2. Previous long-term use of benzodiazepines or opioid analgesics; 3. Drug or alcohol addicts; 4. Pregnant and lactating women; 5. Study drug allergy or other contraindication; 6. Participating in other clinical drug studies.

Design outcomes

Primary

Measure	Time frame
Pediatric Clinical Sedation Scoring System (RASS) score;Critical Care Patient Pain Assessment (CPOT) score;BIS monitoring value;Adverse reaction rate;	—

Secondary

Measure	Time frame
Sedation compliance rate;Duration of mechanical ventilation;length of stay in ICU;	—

Countries

China

Contacts

Public ContactYu Ning

The Second Hospital of Hebei Medical University

04benshuo065@sina.com+86 15933605613

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026